Revenue rose to 64.6 MSEK in 2025, driven by milestone payments and initial commercialization of the OTSTM Hip system, but net loss widened to -19.2 MSEK. Regulatory approvals and new capital raised position the company for accelerated market expansion in 2026.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.